Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study

埃尔特罗姆博帕格 医学 安慰剂 免疫性血小板减少症 内科学 血小板生成素受体 罗米普洛斯蒂姆 血小板生成素 儿科 外科 血小板 病理 替代医学 造血 生物 遗传学 干细胞
作者
James B. Bussel,Purificación García de Miguel,Jenny M. Despotovic,John D. Grainger,Julián Sevilla,Victor S. Blanchette,Lakshmanan Krishnamurti,Philip Connor,Michèle David,Koh B. Boayue,Dana C. Matthews,Michele P. Lambert,Lisa M Marcello,Malini Iyengar,Geoffrey Chan,Karen Chagin,Dickens Theodore,Christine K. Bailey,Kalpana Bakshi
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:2 (8): e315-e325 被引量:166
标识
DOI:10.1016/s2352-3026(15)00114-3
摘要

The oral thrombopoietin receptor agonist eltrombopag is approved for treatment of adults with chronic immune thrombocytopenia. In the PETIT trial, we aimed to investigate the efficacy and safety of eltrombopag in children with persistent or chronic immune thrombocytopenia.PETIT was a three-part, randomised, multicentre, placebo-controlled study done at 22 centres in the USA, UK, Canada, Spain, France, and the Netherlands. Patients aged 1-17 years with immune thrombocytopenia lasting for 6 months or longer and platelets less than 30 × 10(9) per L who had received at least one previous treatment were enrolled. We enrolled patients into three cohorts consisting of patients aged 12-17, 6-11, and 1-5 years. We established patients' starting doses with an open-label, dose-finding phase with five patients in each cohort. During the dose-finding phase, patients aged 6-17 years started eltrombopag at 25 mg once per day (12·5 mg for those weighing <27 kg) and patients aged 1-5 years received 0·7 mg/kg per day to a maximum of 2 mg/kg unless otherwise approved. We permitted dose adjustments on the basis of platelet response up to a maximum dosage of 75 mg per day. Additional patients were then recruited and randomly assigned (2:1) to receive either eltrombopag or placebo tablets (or oral suspension formulation if aged 1-5 years) once per day for 7 weeks at the previously established doses. Starting doses for the double-blind phase were 37·5 mg/day for patients aged 12-17 years; 50 mg/day for patients weighing 27 kg or more (25 mg for east Asian patients) and 25 mg/day for patients weighing less than 27 kg (12·5 mg once per day for east Asian patients) for patients aged 6-11 years; and 1·5 mg/kg once per day (0·8 mg/kg once per day for east Asian patients) for patients aged 1-5 years. Randomisation was done by the GlaxoSmithKline Registration/Medication Ordering System and both patients and study personnel were masked to treatment assignments. Patients who completed treatment were then enrolled into an open-label phase and all patients could receive up to 24 weeks of eltrombopag. The primary outcome was the proportion of patients achieving a platelet count of 50 × 10(9) per L or more at least once from weeks 1-6 (days 8 to 43) of the randomised phase of the study in the absence of rescue therapy. We assessed efficacy in the intent-to-treat population, which consisted of all patients assigned to treatment, and we assessed safety in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT00908037.Between Oct 2, 2009, and June 22, 2011, we recruited 15 patients, with five patients in each age cohort, into the open-label dose-finding phase who did not progress into the double-blind phase. From March 17, 2010, to Jan 15, 2013, we randomly assigned 67 patients to treatment, with 45 patients assigned to receive eltrombopag (16 children aged 12-17 years, 19 aged 6-11 years, and ten aged 1-5 years) and 22 to receive placebo (eight children aged 12-17 years, nine aged 6-11 years, and five aged 1-5 years). However, two patients assigned to receive eltrombopag did not receive the study drug and one was lost to follow-up, and one patient assigned to receive placebo was given eltrombopag. From weeks 1 to 6, 28 (62%) patients who received eltrombopag, compared with seven (32%) who received placebo, achieved the primary endpoint of platelet count 50 × 10(9) per L or more at least once without rescue (odds ratio 4·31, 95% CI 1·39-13·34, p=0·011). The most common adverse events with eltrombopag were headache (13 [30%] patients receiving eltrombopag vs nine [43%] patients receiving placebo), upper respiratory tract infection (11 [25%] patients vs two [10%] patients), and diarrhoea (seven [16%] patients vs one [5%] patient). Grade 3 or 4 adverse events occurred in five (11%) patients receiving eltrombopag and four (19%) patients receiving placebo, and serious adverse events (four [9%] patients receiving eltrombopag and two (10%) patients receiving placebo) were similarly infrequent in both groups. No thrombotic events or malignancies occurred. Increased alanine aminotransferase concentrations caused two (3%) of 65 patients to discontinue eltrombopag in the open-label phase.Our results showed that eltrombopag could be used to increase platelet counts and reduce clinically significant bleeding in children with persistent or chronic immune thrombocytopenia. Prevalence of increased liver laboratory values was similar to that seen in adults.GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善莫大焉发布了新的文献求助10
刚刚
刚刚
1111完成签到,获得积分10
1秒前
寒冷忆山发布了新的文献求助10
2秒前
ccc完成签到 ,获得积分10
3秒前
3秒前
3秒前
核桃发布了新的文献求助30
3秒前
新海天发布了新的文献求助10
4秒前
4秒前
皮皮发布了新的文献求助10
5秒前
珍珠奶茶发布了新的文献求助10
5秒前
上官若男应助洋洋羊采纳,获得10
6秒前
7秒前
avocadoQ完成签到 ,获得积分10
7秒前
万能图书馆应助善莫大焉采纳,获得10
7秒前
ifanyz完成签到,获得积分10
8秒前
冷静凌旋发布了新的文献求助10
8秒前
零点零壹发布了新的文献求助10
8秒前
kingwill应助林一采纳,获得20
8秒前
皮克斯完成签到 ,获得积分10
8秒前
传奇3应助卡卡卡卡卡卡采纳,获得10
8秒前
wengi94发布了新的文献求助10
9秒前
高金龙完成签到 ,获得积分10
10秒前
852应助runer采纳,获得10
10秒前
10秒前
10秒前
Orange应助邵shuo采纳,获得10
11秒前
12秒前
薛梦希完成签到 ,获得积分10
13秒前
研友_VZG7GZ应助张姣姣采纳,获得10
13秒前
xinlu发布了新的文献求助10
14秒前
tj完成签到,获得积分20
15秒前
临界完成签到,获得积分10
15秒前
枫叶发布了新的文献求助10
15秒前
xin完成签到,获得积分10
16秒前
16秒前
18秒前
18秒前
18秒前
高分求助中
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Mobilization, center-periphery structures and nation-building 600
Introduction to Strong Mixing Conditions Volumes 1-3 500
Technologies supporting mass customization of apparel: A pilot project 450
China—Art—Modernity: A Critical Introduction to Chinese Visual Expression from the Beginning of the Twentieth Century to the Present Day 430
Multichannel rotary joints-How they work 400
Tip60 complex regulates eggshell formation and oviposition in the white-backed planthopper, providing effective targets for pest control 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3794928
求助须知:如何正确求助?哪些是违规求助? 3339887
关于积分的说明 10297885
捐赠科研通 3056485
什么是DOI,文献DOI怎么找? 1677034
邀请新用户注册赠送积分活动 805104
科研通“疑难数据库(出版商)”最低求助积分说明 762333